While a lack of TRAIL receptors predicts resistance to TRAIL targeted therapies as shown in neuroblastoma [297], there is no definite correlative link between total DR protein expression levels and the sensitivity of TRAIL [51,163,298]. Here, TNFSF10 is linked to neuroblastoma.